https://doi.org/10.55788/7369dcc5
PD is characterised by alpha-synuclein accumulation, changes in gut microbiota composition, impairment of the intestinal epithelial barrier (IEB), and enteric neurogenic/immune/inflammatory changes. “The intestinal system is not only impaired by PD, but can also be a culprit,” said Dr Gabriele Bellini (University of Pisa, Italy) [1]. An imbalance in neuro-immune, brain-gut axis could lead to neuroinflammation and intestinal dysmotility. Furthermore, gut microbiota alterations, frequently found in PD patients, could very well favour bacterial translocation with an increased intestinal permeability. This could result in enteric neuroinflammation which could favour the misfolding and aggregation of alpha-synuclein. Dr Bellini and his group therefore set up a study to evaluate:
- Changes in faecal microbiota composition;
- Changes in the intestinal mucosal barrier that are capable of altering intestinal permeability;
- Alterations of inflammatory markers in plasma and stool.
Enrolled were 19 PD patients (14 men) and 19 healthy controls. They underwent motor and cognitive evaluations, laboratory (plasma and stool) evaluations, as well as morphological evaluations using colon biopsies: epithelial mucins, collagen fibres, Claudin-1 tight junction, and S-100-positive glial cells.
Looking at changes in faecal microbiota, PD patients had a significantly different alpha-diversity, which was not the case for beta-diversity. Butyricimonas, a short-chain fatty acid-producing bacterium that plays an important role in colonic T cell differentiation, was reduced. Morphological results in PD patients showed an increase in acidic mucin production and in collagen density, a reduced expression of Claudin-1, and an increase of S-100-positive glial cells. The endoscopic exam did not reveal a macroscopic inflammatory process. Compared with controls however, there were significantly higher levels of faecal IL-1beta (P<0.01) and of faecal TNF (P<0.05). Dr Bennini: “This allows for the hypothesis that PD patients have a mild form of intestinal inflammation.”
- Bellini G, et al. Intestinal histomorphological and molecular alterations in patients with Parkinson’s disease: results from a pilot study. OPR-059, EAN 2022, 25–28 April, Vienna, Austria.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Gene variants impact survival in monogenic Parkinson’s disease Next Article
Acute stroke management: from time window to tissue window? »
« Gene variants impact survival in monogenic Parkinson’s disease Next Article
Acute stroke management: from time window to tissue window? »
Table of Contents: EAN 2022
Featured articles
Letter from the Editor
Overarching Theme
Migraine
Targeting cortical activation by transcranial magnetic stimulation
Erenumab more than doubles plasma CGRP levels
Over a third of patients responds late to CGRP antibodies
Multiple Sclerosis
When to start, switch, and stop MS therapy: Real-world evidence counts
Updated EAN-ECTRIMS guideline on pharmacological MS treatment
Gut microbiota composition associated with disability worsening
Teriflunomide in children with MS: final results of TERIKIDS
Estimating brain age in MS: machine learning versus deep learning
Ofatumumab improves cognitive processing speed
Parkinson’s Disease
Intestinal alterations in patients with Parkinson’s disease
Gene variants impact survival in monogenic Parkinson’s disease
Cerebrovascular Disease and Stroke
Most acute stroke patients have undiagnosed risk factors
Absence of Susceptibility Vessel Sign points to malignancy in stroke patients
Acute stroke management: from time window to tissue window?
Epilepsy
Seizure forecasting with non- and minimally-invasive devices
Real-world efficacy of cenobamate in focal-onset seizures
Possible new biomarker for early neuronal death in mesial temporal lobe epilepsy
COVID-19
COVID-19 elevates risk of neurodegenerative disorders
More headaches in adolescents during COVID-19 pandemic
AstraZeneca vaccination and risk of cerebral venous sinus thrombosis
Large impact of COVID-19 on dementia diagnosis and care
Miscellaneous
Tau autoimmunity associated with systemic disease
Long-term effects of avalglucosidase alfa in late-onset Pompe disease
European survey of patient satisfaction in the treatment of cancer-related neuropathic pain
Related Articles
August 22, 2022
Tau autoimmunity associated with systemic disease
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com